Physician profile
Donald T Eagle
NPI 1326086760
$2,703.37
in general payments reported to CMS, 2019-2025
23 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $253 · 2021: $462 · 2022: $507 · 2023: $427 · 2024: $348 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,178.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $534.44 | 2020-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $534.42 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amarin Pharma, INC. | $247.92 | 2019-2022 | |
| Novo Nordisk INC | $214.54 | 2020-2024 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $165.65 | 2021-2023 | |
| Glaxosmithkline, LLC. | $150.39 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $131.33 | 2020-2024 | |
| Boston Scientific Corporation | $128.91 | 2022 | |
| Janssen Pharmaceuticals, INC | $102.12 | 2019 | |
| Lilly USA, LLC | $101.45 | 2022-2025 | Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $44.75 | 2021-2023 | |
| Exact Sciences Corporation | $41.73 | 2024 | Cologuard Collection Kit |
| Lundbeck LLC | $41.57 | 2023 | Rexulti |
| Abbvie INC. | $41.06 | 2021-2022 | |
| Corcept Therapeutics | $40.42 | 2025 | Korlym |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $37.90 | 2020-2021 | |
| Abbott Laboratories | $28.58 | 2022 | |
| Paratek Pharmaceuticals, INC. | $23.16 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.96 | 2024 | Jardiance |
| Astellas Pharma US INC | $21.34 | 2020 | |
| Daiichi Sankyo INC. | $19.08 | 2022 | |
| Merck Sharp & Dohme LLC | $17.14 | 2021 | |
| Seqirus USA INC | $13.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Eagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.